| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | b4Gal-T1; B4GALT1; B4GT1; Beta-1; 4-galactosyltransferase 1 |
| Entrez GeneID | 2683; |
| WB Predicted band size | 44kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse |
| Immunogen | Synthesized peptide derived from C-terminal of human B4GALT1. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是关于B4GALT1抗体的3篇参考文献示例(文献为虚构，仅供格式参考)：
---
1. **文献名称**: "B4GALT1 overexpression promotes tumor invasiveness in colorectal cancer via glycosylation-mediated integrin activation"
**作者**: Zhang L, et al.
**摘要**: 研究通过免疫组化及Western blot分析，发现B4GALT1在结直肠癌组织中高表达，其通过调控整合素β1的糖基化增强肿瘤细胞迁移和侵袭能力，提示B4GALT1抗体可作为潜在预后标志物。
2. **文献名称**: "B4GALT1 autoantibodies as a novel biomarker for early-stage Alzheimer's disease"
**作者**: Thompson R, et al.
**摘要**: 该研究在阿尔茨海默病患者的脑脊液中检测到B4GALT1自身抗体水平升高，表明其异常糖基化可能参与β-淀粉样蛋白沉积，B4GALT1抗体检测或为早期诊断提供新途径。
3. **文献名称**: "Structural and functional characterization of B4GALT1 using monoclonal antibodies"
**作者**: Suzuki H, et al.
**摘要**: 通过制备特异性单克隆抗体，解析B4GALT1的酶活性结构域，证实抗体可抑制其催化功能，为开发靶向B4GALT1的抑制剂奠定基础。
---
注：以上文献为示例，实际研究中请通过PubMed或Google Scholar检索真实发表的论文。
B4GALT1 (β-1.4-galactosyltransferase 1) is a key enzyme in the glycosylation pathway, catalyzing the transfer of galactose to N-acetylglucosamine residues in glycoproteins and glycolipids. This enzyme is critical for synthesizing lactose in mammary glands and modifying glycoconjugates involved in cell adhesion, signaling, and immune response. Dysregulation of B4GALT1 has been linked to congenital disorders of glycosylation (CDGs), cancer metastasis, and neurological conditions, highlighting its biological and clinical significance.
Antibodies targeting B4GALT1 are essential tools for studying its expression, localization, and function. They enable detection of the protein in tissues or cultured cells via techniques like Western blotting, immunohistochemistry, and immunofluorescence. Such antibodies also facilitate research into disease mechanisms—for example, investigating altered glycosylation patterns in tumors or validating B4GALT1 as a biomarker. Commercial antibodies are typically raised against specific epitopes, with validation across species (human, mouse, rat) to ensure cross-reactivity. Researchers must verify antibody specificity using knockout controls or siRNA-mediated knockdown to avoid off-target signals. Recent studies also explore therapeutic applications, such as modulating B4GALT1 activity to influence cell-surface receptor interactions in cancer immunotherapy. Overall, B4GALT1 antibodies serve as vital reagents for both basic research and translational investigations into glycosylation-related pathologies.
×
